These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Systolic Blood Pressure Lowering on the Risk of Stroke. Shihab S; Boucher RE; Abraham N; Wei G; Beddhu S Hypertension; 2022 Apr; 79(4):785-793. PubMed ID: 35114798 [TBL] [Abstract][Full Text] [Related]
27. Systolic and diastolic blood pressure time in target range and cardiovascular outcomes in patients with hypertension and pre-frailty or frailty status. Zhu J; Yang K; Liu W J Clin Hypertens (Greenwich); 2024 May; 26(5):514-524. PubMed ID: 38552135 [TBL] [Abstract][Full Text] [Related]
28. Identifying Patients for Intensive Blood Pressure Treatment Based on Cognitive Benefit: A Secondary Analysis of the SPRINT Randomized Clinical Trial. Ghazi L; Shen J; Ying J; Derington CG; Cohen JB; Marcum ZA; Herrick JS; King JB; Cheung AK; Williamson JD; Pajewski NM; Bryan N; Supiano M; Sonnen J; Weintraub WS; Greene TH; Bress AP JAMA Netw Open; 2023 May; 6(5):e2314443. PubMed ID: 37204788 [TBL] [Abstract][Full Text] [Related]
29. Personalizing the Intensity of Blood Pressure Control: Modeling the Heterogeneity of Risks and Benefits From SPRINT (Systolic Blood Pressure Intervention Trial). Patel KK; Arnold SV; Chan PS; Tang Y; Pokharel Y; Jones PG; Spertus JA Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28373269 [TBL] [Abstract][Full Text] [Related]
30. Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials. Oikonomou EK; Spatz ES; Suchard MA; Khera R Lancet Digit Health; 2022 Nov; 4(11):e796-e805. PubMed ID: 36307193 [TBL] [Abstract][Full Text] [Related]
31. Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey). Bress AP; Kramer H; Khatib R; Beddhu S; Cheung AK; Hess R; Bansal VK; Cao G; Yee J; Moran AE; Durazo-Arvizu R; Muntner P; Cooper RS Circulation; 2017 Apr; 135(17):1617-1628. PubMed ID: 28193605 [TBL] [Abstract][Full Text] [Related]
32. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder RE; Sliwa K; Weber MA; Williams B; Yusuf S Lancet; 2017 Jun; 389(10085):2226-2237. PubMed ID: 28390695 [TBL] [Abstract][Full Text] [Related]
33. Orthostatic Hypotension, Cardiovascular Outcomes, and Adverse Events: Results From SPRINT. Juraschek SP; Taylor AA; Wright JT; Evans GW; Miller ER; Plante TB; Cushman WC; Gure TR; Haley WE; Moinuddin I; Nord J; Oparil S; Pedley C; Roumie CL; Whittle J; Wiggers A; Finucane C; Anne Kenny R; Appel LJ; Townsend RR; Hypertension; 2020 Mar; 75(3):660-667. PubMed ID: 31983312 [TBL] [Abstract][Full Text] [Related]
34. Association of Estimated Pulse Wave Velocity With Survival: A Secondary Analysis of SPRINT. Vlachopoulos C; Terentes-Printzios D; Laurent S; Nilsson PM; Protogerou AD; Aznaouridis K; Xaplanteris P; Koutagiar I; Tomiyama H; Yamashina A; Sfikakis PP; Tousoulis D JAMA Netw Open; 2019 Oct; 2(10):e1912831. PubMed ID: 31596491 [TBL] [Abstract][Full Text] [Related]
35. Assessment of Long-term Benefit of Intensive Blood Pressure Control on Residual Life Span: Secondary Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). Vaduganathan M; Claggett BL; Juraschek SP; Solomon SD JAMA Cardiol; 2020 May; 5(5):576-581. PubMed ID: 32101262 [TBL] [Abstract][Full Text] [Related]